title: The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
abstract: OBJECTIVE
  The comparative effectiveness of medical interventions has recently been emphasized in the literature, typically for interventions in a similar class. Value-based medicine, the practice of medicine based on the value (improvement in quality of life and/or length of life) conferred by medical interventions, allows a measure of comparative effectiveness of interventions across all of health care, no matter how disparate. This report discusses recent comparative effectiveness studies in the vitreoretinal literature.
  
  
  RESULTS
  Vitreoretinal interventions have good to excellent comparative effectiveness compared with commonly utilized interventions across health care, such as treatment for osteoporosis and hyperlipidemia. They also tend to be cost-effective when an upper limit of $100 000/quality-adjusted life-year is utilized.
  
  
  CONCLUSIONS
  Value can be measured using either or both of two outcomes - the quality-adjusted life-year gain and/or the percentage improvement in value - both of which allow for an evaluation of comparative effectiveness, which can be compared on the same scale for every intervention. This value can also be integrated with costs using the outcome of dollars expended per quality-adjusted life-year ($/quality-adjusted life-year, or the cost-utility ratio), which allows a comparison of cost-effectiveness across all interventions. The majority of vitreoretinal interventions confer considerable value and are cost-effective.
authors.affiliation: Center for Value-Based Medicine, Flourtown, USA. mbrown@valuebasedmedicine.com
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Brown
authors.forename: Gary C
authors.initials: GC
authors.lastname: Brown
authors.forename: Heidi C
authors.initials: HC
authors.lastname: Brown
authors.forename: Blair
authors.initials: B
authors.lastname: Irwin
authors.forename: Kathryn S
authors.initials: KS
authors.lastname: Brown
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000379:methods; D006801:Humans; D017075:Laser Coagulation / Q000191:economics* / Q000379:methods; D008268:Macular Degeneration / Q000150:complications / Q000191:economics* / Q000628:therapy*; D010778:Photochemotherapy / Q000191:economics* / Q000379:methods; D011788:Quality of Life; D015861:Retinal Neovascularization / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D014481:United States; D014821:Vitrectomy / Q000191:economics* / Q000379:methods
chemical_list: D020533:Angiogenesis Inhibitors